Author:
ŞANLIDAĞ Gamze,ACET Oğuzhan,ERDEM Hüseyin Aytaç,IŞIKGÖZ TAŞBAKAN Meltem,GÖKENGİN Ayşe Deniz,SİPAHİ Oğuz Reşat,PULLUKÇU Hüsnü
Publisher
Antibiyotik ve Kemoterapi Dernegi
Reference22 articles.
1. Amela C, López-Gay D, Alberdi JC, Castilla J. Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients. Eur J Epidemiol. 1996 Feb;12(1):91-2. https://doi.org/10.1007/BF00144435.
2. 2. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg. 2017;96(1):24-45. https://doi.org/ 10.1093/cid/ciw742.
3. 3. Aslan G, Yapıcı G. Pandemi döneminde ihmal edilen enfeksiyonlar. Turk Mikrobiyol Cemiy Derg. 2021;51(3):214-24. https://doi.org/ 10.5222/TMCD.2021.43660
4. 4. Centers for Disease Control and Prevention. Revised Surveillance Case Definition for HIV Infection. MMWR. 2014 63(RR03);1-(erişim tarihi: 30.03.2021)
5. 5. De la Rosa R, Pineda JA, Delgado J, et al. Incidence of and Risk Factors for Symptomatic Visceral Leishmaniasis among Human Immunodeficiency Virus Type 1-Infected Patients from Spain in the Era of Highly Active Antiretroviral Therapy. J Clin Microbiol. 2002;40(3):762. https://doi.org/ 10.1128/JCM.40.3.762-767.2002